

# Index

Note: Page numbers in *italics* refer to figures and tables.

- access-based advocacy 266  
acid-mediated invasion model 103, *104*  
acute lymphoblastic leukaemia (ALL)  
  pharmacogenomic testing 261, 265  
  racial disparities in outcome 269  
advocacy, access-/evidence-based 266  
agent-based modelling 86  
aircraft, decoupling mechanisms 32  
Alzheimer's disease risk 267  
angiogenesis 73  
  molecular species 73–6  
  promotion 99  
  tumour-induced 74–6  
  VEGF-induced 99–100  
angiogenesis models 60, 73–8  
  continuum 76, 77  
  discrete 76, 77  
  hybrid 76–7  
  mechanochemical 76  
  methodologies 76–8  
  response models 78  
  treatment response 81–2  
  vessel structure stabilizations 77–8  
angiopoietins 74  
anthracyclines 133  
apolipoprotein E4 allele 267  
apoptosis evasion 11  
artificial intelligence techniques 68  
atoms, three-dimensional arrangement 127  
AUTODOCK 137, 138  
automatic flight control system (AFCS) 32  
Available Chemical Dictionary (ACD) 138  
Bayesian networks 86  
BCR-ABL ATP-binding pocket 53  
bevacizumab 53  
BiDil 269  
binding energy prediction 137  
BioBank (UK) 239–40  
Biocarta 84  
bioinformatics 96  
  data leakage risks 253–4  
  informed consent 239–40  
  NCI infrastructure development 158–62,  
  *163, 164*  
  research team confidentiality  
  responsibility 245  
  social concerns 267–8  
  structural 127–38  
  *see also* crystallography, macromolecular;  
  molecular modelling  
biological complexity 7–8  
  constitutive 9–11  
  dynamic 9, 11–12  
  evolved 9, 12–14  
  *see also* systems biology  
Biomedical Informatics Research Network  
  (BIRN) 164, 165–6  
biomedical software, high-risk cancer cell  
  clusters 216–17  
  SoDIS analysis 224–5, 226, 227–8, 229–30  
biosimulation 110  
biotechnology companies, rare disease  
  research 263–4  
BLASTN program 180

- blood flow 74–5
  - mechanical stimulus 98
- blood vessels, shear forces/stresses 74–5, 98
- Boolean network 78, 85
  - probabilistic 86
- Boolean–Bayesian hybrid model 86
- breast cancer
  - molecular marker guidelines 260–1
  - racial disparities in outcome 268
  - technology failure 266
  - see also* trastuzumab
- British Medical Association, professional guidance 249
- Byzantine Generals Problem 33–4
- caARRAY database 163
- CaBIG (Cancer Biomedical Information Grid) 49
- c-abl 128, 129
- caCORE 6, 21
  - infrastructure 162
- caIMAGE database 159
- Caldicott Guardians 206–7, 248
- Caldicott Report (1997) 247–8
- caMOD (Cancer Model Organisms Database) 160, 161
  - application 162
- cancer
  - dormancy 37
  - mortality 185
  - signals 171–2
  - susceptibility modelling 167
  - see also* treatment resistance
- cancer cells
  - acidification of environment 103
  - clonogenic density 114
  - cluster identification program 216–17
    - geometrical of discretizing mesh 112, 114
    - high-risk cluster identification 216–17
      - SoDIS analysis 224–5, 226, 227–8, 229–30
  - hypoxia-induced quiescence 100
  - phenotypes 8
  - robustness 7, 11, 30
  - subclusters 34
- Cancer Genome Anatomy Project (CGAP) 172
- Cancer Molecular Analysis project 46
- cancer registry information 201
- cancer research communities, meeting needs 188–9, 190
- cancer robustness theory 29–40
  - cancer system 34–6
  - computational tools 39–40
  - evolvability 32–4
  - mechanisms 31–2
  - therapy strategies 36–8
  - trade-offs 32–4
  - treatment efficacy index 38–9
- cancer systems
  - complexity 97
    - constitutive 9–11
    - dynamic 9, 11–12
    - evolved 9, 12–14
    - taxonomy 9–14
  - feedback loop control 38
  - instability 111
  - modelling 14–16, 17–19, 20
  - robust 34–6
  - simulation 14–16, 17–19, 20
- CancerGRID 6, 22
- carcinogenesis 101
- carcinoma nodules 65
- Cartesian coordinate frame 127
- C-Change – Collaborating to Conquer Cancer 188
- cdk4 drug design 135
- cDNA sequences 172–3, 175
  - full-length 178, 180
- cDNA xProfiler 175–6
- cell cycle
  - hypoxia-induced arrest 100
  - phases 112
- cell–cell interactions 98
- CellML 24
- cellular automata 68–9, 72–3
  - formalisms 70–1, 72–3
  - hybrid approach 71, 97, 103–4
  - lattice–gas two-dimensional approach 71
  - models 98, 99
  - stochastic model 70–1
  - three-dimensional models 97
  - treatment response models 82
  - two-dimensional models 97
- cellular evolution 12–14
- Center for Systems Biology (US) 166
- Central Office of Research Ethics Committees (UK) 205
- chemical reaction–diffusion dynamics 71
- chemotaxis 71
  - angiogenesis modelling 77

- chemotherapy 119
  - response simulation 118–19
- chromosome 1q25, expressed sequences 182
- chromosome 21
  - gene identification 181
  - novel transcripts 181–2
- chromosome 22, gene identification 181
- chromosome instability 34, 37
- chromosome mutations 13
- chronic myeloid leukaemia (CML)
  - treatment response modelling 80, 81
  - see also* imatinib
- c-kit receptor tyrosine kinase 128
- CLEF (Clinical E-Science Framework) 22
  - project approach 251–2
- client needs 218
- clinical care, health data 235–6
- clinical decision-making, error avoidance 53
- clinical information systems 201
- Clinical Laboratory Improvement Amendments (1988, US) 258, 259
- clinical research database, accountability 239
- clinical trials
  - ethical issues 233–55
  - EU Directive 243
  - information systems 201
- clinical utility 261
- colorectal cancer
  - chemotherapy clinical trial 187
  - tissue use 205–6
- common mode failure 36
- complex systems
  - simulations 86–7
  - see also* biological complexity; systems biology
- complex trait analysis 167
- computational systems biology 5
- computer simulation, treatment response 109–21
- conceptual models 7–8
- confidentiality
  - bioinformatics research team
    - responsibility 245
  - NHS Code of Practice 248
  - patient information 206–7
  - policies 252, 253
  - professional guidance 249
  - UK Common Law 244
- consent/informed consent
  - access to health records 237
  - bioinformatics 239–40
  - boundaries 240
  - DNA analysis 247
  - documented 236
  - durability 240
  - explicit/express 239
  - obligations 248
  - obtaining from patients 207, 250
  - patient-identifiable data 234–5
  - personal information use 239–40
  - pre-existing 250
  - specimens for medical research 247
- constructive models 62
- control theory 111
- Conway's Game of Life 72
- cost-effectiveness analysis 261, 262
- Council of Europe Recommendation on health data 242–3
- cryoablation of prostate 119
- crystal structures 131, 132
- crystallography, macromolecular 129–35
  - high-throughput methods 134
  - structure storage 131–2
- Darwinian environment 100, 101, 102–3
- data
  - anonymized 207, 250–2
  - computational management 5
  - depersonalization 242
  - electronic for patients in clinical trials 233–55
  - electronically-held 236–7
  - genetic 243
  - integration 20–2, 46–7
  - leakage of research 253
  - machine analysis 53
  - resource availability 50
  - sharing 46–7, 50, 52
    - drug design 52–3
  - standards 20–4
  - see also* health data; patient-identifiable health data
- data mining 83–4
  - computational 5
  - sequence databases 172
  - vertical genomics 16, 17–19, 20
- data protection, EC directive 242
- Data Protection Act (1998, UK) 204, 206, 244–5
  - anonymized data 250–1
- databases
  - information storage 178
  - sequence mining 172
  - see also* named databases

- data-driven research 6, 15
- decision support systems, computer-based 53
- decoupling 32
- decoy use 38
- de-identification 235
  - techniques 251–2
- Department of Health (UK) policies 247–8
- devices, regulation 259
- diabetes mellitus 34
- diagrammatic cell language (DCL) 86
- differential equations 63, 69, 79
  - see also* ordinary differential equations;
  - partial differential equations
- diffusion-reaction models 98
- Digital Gene Expression Displayer (DGED) 175–6
- DIP 84
- disclosure
  - inappropriate 252, 253–4
  - professional guidance 248–9
- discrete state cell-cycle-based radiotherapy response model 120
- discretizing mesh 112, 114, 119
- disease
  - minority populations 268–9
  - orphan 263–4
  - system failure 34
- disparities, health 268–70
- DNA analysis, consent 247
- DNA damage, p53 oscillatory expression 32
- DNA microarrays 120
- DOCK 137, 138
- docking program, automated 136, 137–8
- dormancy, cancer 37
- drug(s)
  - candidate screening 131
  - genotype-specific marketing 269
  - molecular targeted 128
  - orphan 263–4
- drug delivery
  - fractal models 86
  - protocols 100
- drug design
  - data sharing 52–3
  - in silico* screening 137–8
  - structure-based 135–7
- drug development 185–209
  - clinical 186
  - Phase 1 190
  - social subsidies 264
- drug discovery, rational 135–7
  - structure determination 131
- dynamic pathway models 60, 83–6
- E-cell 87
- e-GIF 199
- Electronic Health Record (EHR) 236–7
  - accountability 239
  - anonymized repository 251
  - ethical principles 238
  - legal principles 238
- eMICE website 158, 159, 164
- employers, pharmacogenomic test information 267
- endothelial progenitor cells (EPCs) 81–2
- environment
  - Darwinian 100, 101, 102–3
  - perturbations 32–3
- enzyme structures 132, 133
- epidemiological statistical techniques 61
- epidermal growth factor (EGF) pathway 12
  - signal transduction pathway model 85
- ethical framework, National Cancer Tissue Resource 202–4, 207
- ethics
  - clinical trials 233–55
  - Electronic Health Record 238
  - health record information 237–9
  - pharmacogenomics 264–70
  - software design 213–30
  - tissue sample handling 238–9
- ethnic health disparities 268–70
- European Bioinformatics Institute (EBI) 49
- European legislation
  - health data 242–3
  - orphan drugs 264
  - pharmacogenomics 259
- European Union Clinical Trials Directive 243
- evidence-based advocacy 266
- evolution
  - cellular 12–14
  - somatic 101, 102–3
- evolvability 32–3
- robustness 30
- exon/intron boundaries 180
- expressed sequence tags (ESTs) 172, 173
  - clusters 182

- International Database of Cancer Gene
  - Expression 176–7
  - mapping 182
- extracellular matrix composition 74
- FAPESP/LICR Human Cancer Genome
  - Project 172–82
  - methodology 173
  - organization 172–3
  - sequence analysis 173–4
  - tumour transcriptome 175–8, 179, 180–2
- finite difference time domain (FDTD)
  - technique 114
- First Genetics Trust 202
- Food and Drug Administration (US)
  - orphan drugs 264
  - pharmacogenomics regulation 258–60
- formalisms 61–2
  - cellular automata 70–1, 72–3
  - generalized 62–4
  - treatment response models 78
- fractal models 86
- fragility 33
  - robustness trade-off 37
- Freedom of Information Act (2000, UK) 246
- gastrointestinal stromal tumours 128, 187
- gene(s)
  - cancer-related set 176
  - catalogues 175
  - identification 180
  - prediction programs 180
  - stability 7–8
- gene expression
  - modes 171
  - pathway dynamics link 11–12
  - survey 177
- Gene Library Summarizer (GLS) 175–6
- General Medical Council (UK), professional guidance 248–9
- genetic abnormalities 7
- genetic buffering 32
- genetic data, Council of Europe
  - Recommendation 243
- genetic heterogeneity, intratumoural 34, 36–7
  - enhancement by somatic recombination 37
  - molecular-targeted drugs 37–8
- genetic information, patient 238
- genome
  - analysis 180
  - deregulation 8
  - unstable 13
  - see also* human genome
- genomic technologies, health insurers 261–2
- genomics 3, 4
  - integration/interrogation of research results 202
  - structural 134
  - vertical 16, 17–19, 20
- genotypic TPMT testing 261, 265, 269–70
- Gert's morality theory 225
- Gleevec<sup>®</sup> *see* imatinib
- glioblastoma multiforme 116, 117–18
  - temozolomide treatment 119
- Glivec<sup>®</sup> *see* imatinib
- glucose metabolism
  - altered 102
  - anaerobic 103
- glycolysis
  - aerobic 102
  - constitutive upregulation 103
  - inhibition 102
- glycomics 3, 4
- Gompertz function 63–4, 66–7
- good practice, patient information 248
- growth models 60, 62–71
  - avascular 65–6
  - formalisms 66–9
  - non-traditional 69–71
- growth retardation, avascular 66
- haptotaxis, angiogenesis modelling 77
- health
  - disparities 268–70
  - WHO definition 214
- Health and Social Care Act (2001, UK) 207, 246–7
- health data
  - access rights 237, 245
  - anonymized 207, 250–2
  - clinical care 235–6
  - consented research 235–6
  - European legislation 242–3
  - genetic 243
  - ISO standard 241–2
  - key-coding 250

- health data (*Continued*)
  - patient-identifiable 233–40, 240–50
    - flow principles 247–8
    - legislation 240–7
    - policies 247–50
  - protection 250, 252–5
  - pseudonymized 250–2
  - researchers' access to 249
  - secondary use 249–50
  - sharing 246–7
  - UK legislation 244–7
- health information
  - disclosures 248–9
  - genetic of patient 238
  - given to patients 236–7
  - global integration 238
  - NHS governance 248
  - right of access 246
  - third-party access to pharmacogenomic tests 266–7
  - uses 235
- Health Insurance Portability and Accountability Act (US) 268
- health insurers
  - genomic technologies 261–2
  - health disparities 268
  - pharmacogenomic test information 267
- Health Protection Agency (UK) 207
- health records
  - access for research 237
  - durable 237
  - ethical requirements for information 237–9
  - information 236–7
  - retrospective use 250
  - rights to access 237
- healthcare systems, integrated informatics platform engagement 50–1
- healthcare technology evaluation 261–3
- HER2 gene 187
  - expression 261
- Herceptin® *see* trastuzumab
- heuristic models 61
- high optimized tolerance (HOT) systems 33
- high-throughput methods 3–4, 83–4
  - crystallography 134
  - eukaryotic protein expression 134
  - macromolecular crystallography 131
- HIV/AIDS, decoy virus use 38
- homology modelling 135
- HORUS model 248
- host–tumour dynamics 7
  - feedback control 38
- Hsp90, genetic buffering 32
- Human Brain Project 164
- Human Cancer Genome Project, *see* FAPESP/LICR Human Cancer Genome Project
- human genome
  - economic gain from project 52
  - genes 180
  - proteins 134
- human rights, health disparities 268
- Human Rights Act (1998, UK) 245–6
- Human Tissue Authority (UK) 206
- Human Tissue Bill (2004, UK) 202–3, 204–7, 247
  - patient-identifiable health data 234
- hybrid models 60–1
- hypothesis generation/validation 186, 190
- hypothesis-driven research 6, 15
- hypoxia 100
- hypoxia-induced factor-1 (HIF-1) 99
  - overexpression 35
  - up-regulation 38
- ideological models 62
- imatinib 36, 53, 128–9, 187
- immunity–tumour interaction 70
- immunohistochemistry, diagnostic procedures 148
- immunotherapeutic strategies 80
- impossibility 225, 227
- in silico* experimentation 59, 60
- in silico* libraries 136, 137–8
- in silico* oncology 110
- in silico* screening for drug design 137–8
- informatics
  - crystallographic 131–4
  - ethics in clinical trials 233–55
  - Mouse Models of Human Cancers Consortium programme 156–8
  - NCRI strategy 191
  - in silico* screening 137–8
  - social concerns 267–8
  - structural 131–4
  - tools 175–6
  - see also* bioinformatics
- informatics platform, integrated 45–54
  - benefits 51–3
  - building 46–7
  - data sharing 50, 52–3
  - development 49–51

- drug design 52–3
- education 50
- healthcare system engagement 50–1
- integration 49
- resource availability 50
- reward systems 49–50
- training 50
- information *see* health information; patient information; personal information
- information systems, National Cancer Tissue Resource 194–5
- architecture 195–6, 197–8, 199–204
- information technology (IT)
  - NHS 196, 199
  - UK National Programme 199
- informed consent *see* consent/informed consent
- Integrated Database of Human Cancer (IDHC) 178, 179
  - data sets 180
  - gene discovery use 180–2
- integration programmes 49
- International Conference on Harmonization 264
- International Database of Cancer Gene Expression 175, 176–7
- International Medical Informatics Association 225
- International Organization for Standardization (ISO) 241–2
- In-Vitro Diagnostic Devices Directive (EU) 259
- ISOG avascular tumour growth simulation model 112–14
  - discretizing mesh 119
- Joint Clinical Information System (Cambridge, UK) 199
- justice, health disparities 268
- KEGG 84
- key-coding 250
- kinases, homology modelling 135
- knowledge discovery 5–6
  - mathematical modelling 15
  - wet–dry cycles 6
- lead compounds, perturbation selection 40
- legislation
  - Electronic Health Record 238
  - European 242–3, 259, 264
  - patient-identifiable health data 240–7
  - pharmacogenomics 258–60
  - tissue sample handling 238–9
  - tissue use 202–7
  - UK 244–7
  - US mechanisms 260
- legitimate infringement 225, 227
- leukaemia *see* acute lymphoblastic leukaemia (ALL); chronic myeloid leukaemia (CML)
- Library Finder 175–6
- linear quadratic (LQ) model 79, 83
- linkage mechanisms, longitudinal 247
- LISA system 53
- literature, manual curation 145, 146
- locality-interaction modelling 69
- logistic growth function 64
- macromolecule structures 131–2
- macrophages, chemotaxis in tumour cluster 35
- malignant phenotype
  - acquisition 100
  - properties 101–2
- MAP kinase pathway 12
  - overexpression 85
- mathematical modelling 59–88, 95–6
  - complex biological system simulation 86–7
  - computational 5
  - diffusion-reaction 98
  - efficacy–toxicity 119
  - multiscale 96–8
  - types of models 60–1
  - see also* angiogenesis models; cellular automata; dynamic pathway models; growth models; population models; treatment response models; tumour(s), vascular modelling
- MATLAB 85
- MDR1 gene 35
- medical informatics, social concerns 267–8
- Medical Research Council (UK) professional guidance 249
- 6-mercaptopurine 265
- metabolic activity, spatial distribution 113
- metabolic networks 10
- metabolomics 3, 4
- metastases, tumour vascularization 73
- Michaelis–Menten equations 84–5

- microarrays 83–4, 120
  - high-throughput DNA 84
- model organisms 166
- models/modelling
  - agent-based 86
  - cancer
    - models database 162, 163
    - resistance 119, 167
    - susceptibility 167
    - systems 14–16, 17–19, 20
  - cancer biology model connections 164
  - conceptual 7–8
  - constructive 62
  - heuristic 61
  - homology 135
  - ideological 62
  - integrating with human cancer research 155–67
  - molecular 135–8
  - multicellular tumour spheroids (MTS)
    - 64–6, 68, 71
  - normative 61
  - NTCP of radiotherapy-induced normal tissue
    - complications 120
  - pedagogical 61
  - proliferative cell behaviour 86
  - response behaviour 78–83
  - spatiotemporal of cell 84
  - systems vertical genomics 16, 17–19, 20
  - terminology 60
  - tumour vascular 98–100
  - vascular 98–100
  - see also* mathematical modelling; Monte-Carlo models; mouse models
- modularity, perturbation isolation 31
- molecular marker guidelines 260–1
- molecular modelling 135–8
- molecular networks, integration into tumour
  - behaviour simulations 120
- molecular signatures 186
- molecular-targeted drugs 37–8
- molecules, three-dimensional architecture of
  - surface 127–8
- Monte-Carlo models
  - method 83
  - radiotherapy response simulation 114, 115, 116, 117–18
- morality theory of Gert 225
- mouse models
  - database 157
  - development 144
  - genetic 164
  - histopathology image collections 159, 160
  - manual curation of data 160
  - terminology consistency 159
- Mouse Models of Human Cancers Consortium (MMHCC) 156
  - databases 160–1
  - domains 165
  - informatics 156–8
  - tumour histopathology images 161
- Mouse Phenome Project 164
- Mouse Tumour Biology (MTB) database
  - 143–52
  - connecting with related databases 150
  - content 145
  - data acquisition 145–8
  - histopathology images 147–8
  - Tumour Frequency Grid 148, 151
  - using 147, 148, 149–50, 151
- mRNA sequences 173, 174
- multicellular tumour spheroids (MTS)
  - models 64–6, 68, 71
- Multi-centre Research Ethics Committee (MREC) 206, 207
- multi-drug resistance 35
- multiset rewrites 76
- mutagenesis, discrete time stochastic
  - model 86
- mutations 7–8
  - bystander 8
  - cancer genes 13
  - chromosomal 13
  - modelling 86
  - oncogene 7–8
  - randomness 13
- National Cancer Institute (US) 155–6
  - bioinformatics infrastructure
    - core 162
    - development 158–62, 163, 164
  - Cancer Genome Anatomy Project 175–6
  - Center for Bioinformatics (NCICB) 49, 156, 158–62, 163, 164
  - Integrative Cancer Biology Program 166
  - medical imaging infrastructure 161
  - Molecular Analysis of Cancer 162–3
  - Mouse Models of Human Cancers Consortium programme 156–64
  - small animal imaging 161

- National Cancer Research Institute (UK) 187–8
  - Consumer Liaison Group 207
  - informatics platform 47–9
  - Informatics Strategy 191
- National Cancer Tissue Resource 191–208
  - planning matrix 48–9
  - Strategic Framework for the Development of Cancer Research Informatics 6, 21–2
  - strategic partnerships 49
- National Cancer Tissue Resource (UK) 191–208
  - access to academic researchers/industry 202
  - clinical outcome information 192
  - components 193, 196, 197–8, 199–202
  - consent 204–7
  - donor information 200–1
  - ethical approval 207
  - ethical framework 202–4
  - information system 194–5
    - architecture 195–6, 197–8, 199–204
    - functionality 194–5
  - integration/interrogation of results 202
  - legal framework 202–4
  - local acquisition centres 196, 197, 199
  - local centre systems 201
  - new systems 200–1
  - patient identity protection 203–4
  - patient information confidentiality 206–7
  - sample information 200, 201
  - security 203–4, 207
  - tissue supply 192
  - tracking systems 199–200
  - unintended identification 207
  - workflow processes 198
- National Cancer Waiting Times Project (UK) 199–200
- National Comprehensive Cancer Network (US) 260–1
- National Data Spine (UK) 204
- National Health Information Infrastructure (US) 267–8
- National Health Service (UK)
  - Confidentiality Code of Practice 248
  - information governance 248
  - integrated informatics platform
    - engagement 50–1
  - IT systems 196, 199
  - molecular revolution benefits 185
  - paraffin-embedded tissue archive 192
- National Institute for Clinical Excellence (UK) 262–3
- National Partnership for Advanced Computational Infrastructure (US) 164–5
- National Translational Cancer Research Network (NTRAC) 188–9, 191
- neovascularization of capillaries 73
- network biology 10–11
- neurobiology information 164
- NF- $\kappa$ B
  - signal transduction pathway 85
  - treatment response model 80
- normative models 61
- NTCP model of radiotherapy-induced normal tissue complications 120
- nuclear magnetic resonance (NMR)
  - spectroscopy
    - macromolecular structure
      - determination 129
      - macromolecular structure storage 131–2
- Nuffield Council in Bioethics 263, 264, 266
- Nuffield Trust, professional guidance 249–50
- omic technologies 3, 4, 5
- oncogene/pathway addiction 7
- oncogenes
  - defect correction 7
  - mutations 7–8
- ONSA (Organization for Nucleotide Sequencing and Analysis) 172
- ontologies, translational cancer research 22–3
- open reading frame ESTs *see* ORESTES
- ordinary differential equations (ODE) 67, 68, 69
  - dynamic pathway models 85, 86
  - treatment response models 80–1, 82
- ORESTES sequences 173–4, 176
  - chromosome 22 181
  - integration with genome sequence 180
  - methodology 173
- orphan diseases/drugs 263–4
- Orphan Drug Act (1983, US) 263–4
- OWL ontology exchange language 23
- oxygen
  - concentration heterogeneity effects 98–9
  - enhancement ratio (OER) 79
- p27 100
- p53 oscillatory expression on DNA
  - damage 32

- partial differential equations (PDE) 67, 69, 71
  - treatment response models 82
- Pasteur effect 102
- pathobiology of cancer 7
- pathology information systems 201
- pathways
  - conceptualization 84
  - data 84
  - dynamics and gene expression link 11–12
  - see also* dynamic pathway models
- patient(s)
  - care and risk assessment 217
  - choice in pharmacogenomics 266
  - consent 234–5
    - documented 236
    - informed 207
  - de-identification 235
  - electronic data ethics in clinical trials 233–55
  - genetic information 238, 243
  - health record information 237–9
  - identity
    - protection 203–4, 206–7
    - unintended identification 207
  - information given 236–7
  - personal information classes 235–7
  - rights 218
- patient administration systems 201
- patient information
  - confidentiality 206–7
  - disclosures 248–9
  - good practice 248
  - personal
    - classes 235–7
    - obtaining consent for use 239–40
    - professional guidance 248–50
- Patient Information Advisory Group (PIAG) 207
  - personal health data sharing 246
- patient-identifiable health data 233–40
  - flow principles 247–8
  - legislation 240–7
  - policies 247–50
  - professional guidance 248–50
- pedagogical models 61
- personal information
  - classes 235–7
  - obtaining consent for use 239–40
  - see also* health data; health information; patient information
- perturbations
  - computational analysis 40
  - environmental 32–3
  - robustness against 33
- Peterborough Tissue Bank 202
- P-glycoprotein (P-gp) 35
- pharmaceutical companies, economic incentives
  - for rare disease research 263–4
- pharmacogenomics 14, 257–70
  - access 268
  - benefits 261–3
  - clinical utility 261
  - costs 261–3
  - drugs 258–61
  - economics 263
  - ethics 264–70
  - evaluation criteria 260–1
  - family member issues 266–7
  - genotype-specific marketing of drugs 269
  - health disparities 268–70
  - legislation 258–60
  - off-label use 259
  - patient choice 266
  - physician competence 265–6
  - psychosocial issues 266
  - regulations 258–60
  - sponsors 259–60
  - technology failure 266
  - tests 258–61
    - third-party access to information 266–7
  - therapies tailored to minority groups 269
  - unapproved use 259
  - White privilege perpetuation 269
- PharmGKB pharmacogenomics database 46
- phenotype
  - cancer 8
  - malignant 100, 101–2
- physicians, competence in
  - pharmacogenomics 265–6
- Physiome Project 105
- platelet-derived growth factor (PDGF) 74–5
- policies
  - confidentiality 252, 253
  - patient-identifiable health data 247–50
- population models 100–3
- positron emission tomography,
  - fluoro-deoxyglucose (FdG PET) 102
- PROCHECK algorithm 132
- professional guidance, patient
  - information 248–50

- proliferative cell behaviour modelling 86
- prostate cryoablation 119
- Protégé-2000 23
- protein(s)
  - folding pattern predictions 135
  - microarrays 120
  - structures 132, 133
    - prediction 135
- Protein Data Bank (PDB) 131–3
  - human genome proteins 134
- Protein Database 129
- protein kinase superfamily 133
- protein–drug structures 133
- protein–ligand complexes 132
- protein–protein interaction data 84
- proteomics 3, 4
  - integration/interrogation of research results 202
- pseudodormancy 37
- public health, health disparities 268
  
- quality-adjusted life years (QALYs) 262–3
- QUASAR clinical trial, tissue use 205–6
  
- racial health disparities 268–70
- radiation, ionizing, signalling pathway
  - overexpression 85
- radiochemotherapy, electric pulse local application 119
- radiotherapy
  - discrete state cell-cycle-based response model 120
  - NTCP model of normal tissue complications 120
  - optimization 83
  - response simulation 114, 115, 116, 117–18
- random walks 76, 77
- reaction diffusion system 98
- regulations for pharmacogenomics 258–60
- research, secondary 249–50
- Research Ethics Committees 205
  - patient-identifiable health data 234
- research repository
  - anonymized 251
  - longitudinal 250
- researcher submissions to databases 145, 146
- resource allocation 263
- Resource Description Framework (RDF) 22
- response behaviour modelling 78–83
  
- risk analysis
  - ethical 217–18
  - software design 215–16
  - statistical 217
- risk identification in software design 214–16
- robustness
  - alternative (fail-safe) mechanisms 31
  - analysis 39–40
  - biological systems 30
  - control 38–9
  - decoupling mechanism 32
  - fragility trade-off 37
  - intrinsic features of systems 32–4
  - mechanisms 31–2
  - modularity 31
    - against perturbations 33
    - system control 31
    - theory of 29–40
  
- SBW (Systems Biology Workbench) 20
- scale-free networks 33
- scar tissue formation 104–5
- SCIPath (Systems Complexity Interface for pathways) project 16, 18–19, 20
- self-organized criticality (SOC) 33
- semantic web technologies 22–4
- serial analysis of gene expression (SAGE)
  - data 177–8
  - Genie web portal 178
  - tags 172, 176, 177, 178
- service concept 218
- signalling
  - networks 10–11, 84–5
  - pathways
    - overexpression 85
    - redundancy 134
    - transduction inhibition 12
    - vertically integrated analysis 16, 18–19, 20
- simulation, terminology 60
- Singapore Tissue Network 188
- slime mould pattern formation 104
- small interfering RNA (siRNA)
  - immunotherapy 80
- socio-economic factors, health
  - disparities 268–70
- software design
  - absence of negative effects on users 218
  - ethics 213–30
  - failure 214
  - fiduciary model 218

- software design (*Continued*)
  - paternalistic model 217–18
  - Project Auditor 219–20
  - project type identification 220
  - responsibilities of designers 218
  - risk identification 214–16
  - surprising impacts 214
- Software Development Impact Statement (SoDIS) 214–16, 218–24
  - Active Concerns Detail Report 228, 230
  - analysis screen 220, 222
  - concerns 228, 229
  - ethical concern identification 222, 223–4
  - goals 218–19
  - mitigation process 223–4
  - potential ethical issue identification 222
  - process 219–24
  - Project Auditor 219–20
  - risk analysis principles 215–16
  - solutions 228, 229
  - stakeholders
    - identification 220, 221, 225, 226, 227–8
    - role identification 220
  - task identification 221
- Software Engineering Code of Ethics and Professional Practice 218
- somatic evolution 100, 102–3
- somatic recombination 37
- Spanish National Tumour Bank 202
- spatiotemporal modelling of cell 84
- specimens for medical research, consent 247
- sponsors, pharmacogenomic 259–60
- stability gene mutations 7–8
- state transitions 112
- statistical analysis of risk 217
- statistical techniques, epidemiological 61
- STI-571 81
- stochasticity, extrinsic 85
- synchrotron sources 130, 131
- systems
  - control robustness 31
  - failures 33–4
  - simulation of complex 86–7
  - understanding 8
  - vertical genomics modelling 16, 17–19, 20
  - vulnerability 14
- systems biology 4–6, 171–2
  - biomolecular networks 10–11
  - complex system simulations 86–7
  - computational 5
  - conceptual models 7–8
  - international initiatives 12
  - mathematical models 53
  - open access tools 17
  - robustness 30
  - simulations of complex 86–7
- Systems Biology Markup Language (SBML) 23–4, 39
- Systems Biology Workbench (SBW) 39
- temozolomide 119
- therapy optimization models 78
- thiopurine methyltransferase (TPMT)
  - genotyping 261, 265
  - racial disparities 269–70
- tirapazamine 119
- tissue(s)
  - annotated with clinical information 187–9, 190, 191
  - anonymized 247
  - ethical principles 238–9
  - genetic information of patient 238
  - legal principles of handling 238–9
  - legislation on use 202–7
  - paraffin-embedded
    - archive 192
    - prospective collection 193
  - residual 247
  - resources 187–9, 190, 191
  - typing 186
  - see also* National Cancer Tissue Resource
- tissue bank information 201
- trade-offs, fragile 33
- Transcript Finishing Initiative 182
- Transcriptome Database, graphical
  - interface 181
- transcriptomes 175–82
- transcriptomics 3, 4
- transforming growth factor  $\alpha$  (TGF- $\alpha$ )
  - overexpression 85
- transforming growth factor  $\beta$  (TGF- $\beta$ )
  - 74–5
  - siRNA immunotherapy 80
- translational cancer research ontologies 22–3
- trastuzumab
  - benefit prediction 261
  - design 52
  - development 186–7

- treatment
  - efficacy index 38–9
  - normal tissue response 120
  - strategies 36–8
  - toxicity response 120
- treatment resistance 8, 11, 29
  - models 167
    - efficacy–toxicity 119
    - multi-drug 35
- treatment response models 60, 78–83
  - cellular automata 82
  - computer simulation 109–21
    - chemotherapy 118–19
    - radiotherapy 114, 115, 116, 117–18
    - tumour growth 111–14
  - formalisms 78
  - mechanistic-based 78
  - radiotherapy optimization 83
  - therapy optimization 78
- tumour(s)
  - altered glucose metabolism 102
  - behaviour simulations 120
  - classification systems 159–60
  - control probability 79
  - dormancy 37
  - expansion 112
  - geometry of imageable lesion 113
  - growth
    - avascular 69–71
    - characters 62
    - early 103
    - simulation 111–14
  - nomenclature 145–6
    - systems 159–60
  - shrinkage 113
  - suppressor mutations 7–8
  - transcriptomes 175–82
  - vascular modelling 98–100
  - vascularization 73
  - see also* growth models
- tumour angiogenic factors (TAFs) 74, 75, 76, 77
  - signalling 77–8
- tumour chords 64–6
- tumour clusters 34, 35
- tumour spheroids
  - formation 112
  - multicellular 64–6, 68
- tumour-associated macrophages (TAMs) 35
  - decoy mechanisms 38
- tumour–host interactions 35
- UK BioBank 239–40
- UK legislation 244–7
- UniGene 178
- vascular endothelial growth factors (VEGF) 74, 75
  - angiogenesis induction 99–100
    - cancer cell secretion 99
- vascular modelling 98–100
- vascularization processes 73
- vasculogenesis 73
- Virtual Cell platform 86, 87
- Virtual Northern 175–6
- virtual sequencing network 172
- von Bertalanffy growth function 64
- Warburg effect 102
- World Health Organization (WHO) health
  - definition 214
- wound healing, scar tissue formation 104–5
- XML syntax 22
  - exchange standards for pathways/models 23–4
- X-ray crystallography 129–35
- yeast model system 39–40

*Index compiled by Jill Halliday*









